Résumé
Sepsis is a life-threatening organ dysfunction resulting from dysregulated host responses to infections.Platelet-related indicators are closely related to the prognosis of sepsis,including platelet(PLT)count,mean plate-let volume(MPV),platelet distribution width(PDW)and platelet aggregation rate(PAR),which can serve as im-portant evaluation indicators for the occurrence and development of sepsis.This paper elaborates the value of plate-let-related indicators in evaluating the prognosis of patients with sepsis,aiming to help clinicians understand the clinical value of monitoring platelet-related indicators in sepsis patients and accurately identify high-risk sepsis pa-tients.
Résumé
<p><b>BACKGROUND</b>Morphologic imaging after radiofrequency ablation (RFA) of liver metastases is hampered by an inflammatory response in the ablation margin, making the identification of local tumor progression (LTP) difficult. The aim of this study was to evaluate the efficacy of early (18)F-FDG PET/CT scanning to monitor the effectiveness of RFA in colorectal liver metastases.</p><p><b>METHODS</b>Twelve patients with 20 metastases were treated with RFA for colorectal liver metastases. They underwent PET/CT within 2 weeks before RFA and within 24 hours after RFA (so termed "early PET/CT"). PET/CT was repeated at 1, 3, and 6 months, and then every 6 months after ablation. The standard of reference was based on available clinical and radiological follow-up data.</p><p><b>RESULTS</b>Early PET/CT revealed total photopenia in 16 RFA-treated metastases, which were found to be without residual tumor on the final PET/CT scan. Three RFA-treated metastases with focal uptake were identified as local tumor progression, which necessitated further treatment. One RFA-treated metastasis with rim-shaped uptake was regarded as inflammation. The results of the early PET/CT scanning were consistent with the findings of the final follow-up.</p><p><b>CONCLUSIONS</b>PET/CT performed within 24 hours after RFA can effectively detect whether residual tumor exists for colorectal cancer liver metastases. The results can guide further treatment, and may improve the efficacy of RFA.</p>